The First Approved C5a Antibody – Vilobelimab
5 July 2023
Vilobelimab is a monoclonal antibody that targets C5a. It is developed by InflaRx NV for the treatment of COVID-19, pyoderma gangrenosum, anti-neutrophil cytoplasmic antibody-associated vasculitis, recurrent cutaneous squamous cell carcinoma, cutaneous squamous cell carcinoma, squamous cell carcinoma, pyoderma gangrenosum with vasculitis, granulomatosis with polyangiitis, and microscopic polyangiitis.